Mikaela Peglow Pinz

Mikaela Peglow Pinz

Auto-generated profile, based on publicly available information

Mikaela Peglow Pinz

Federal University of Pelotas

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2026 in Redox Report
Verified
Journal Article
Open access
RORenata L. De Oliveira
Renata L. De Oliveira
MPMikaela P. Pinz
Mikaela P. Pinz
GVGuilherme T. Voss
Guilherme T. Voss
KRKarline Da C. Rodrigues
Karline Da C. Rodrigues
AVAne G. Vogt
Ane G. Vogt
CLCristiane Luchese
Cristiane Luchese
Alzheimer's disease (AD) is characterized by cognitive impairment and neuropsychiatric disturbances, including depression, both tightly linked to redox imbalance and neuroinflammatory activation. This study investigated whether the selenium-containing compound 7-chloro-4-(phenylselanyl)quinoline (4-PSQ) mitigates behavioral and biochemical alterations in a β-amyloid (Aβ)-induced mouse model of AD through modulation of redox-regulated pathways. Male Swiss mice received intracerebroventricular Aβ (25-35) or saline (3 µL/site) and were treated orally for seven days with 4-PSQ (1 mg/kg), paroxetine (1 mg/kg), or donepezil (1 mg/kg). Depressive-like behavior and memory performance were assessed, followed by determination of plasma corticosterone, reactive species levels, lipid peroxidation, antioxidant enzyme activities, neuroinflammatory mediators, and acetylcholinesterase (AChE) activity in the hippocampus and prefrontal cortex of mice. 4-PSQ significantly reversed Aβ-induced depressive behavior and memory impairment. The compound normalized plasma corticosterone levels, reduced reactive species and lipid peroxidation, and restored antioxidant enzyme activity. It also decreased the expression of inflammatory markers while regulating AChE activity, indicating concomitant modulation of redox, neuroimmune, and cholinergic pathways. By restoring redox homeostasis and attenuating neuroinflammatory responses, 4-PSQ effectively counteracted behavioral and biochemical disruptions associated with Aβ toxicity. These findings support 4-PSQ as a promising selenium-based therapeutic candidate targeting redox-driven features of AD, including comorbid depression and cognitive decline.

19 May 2023 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
MPMikaela Peglow Pinz
Mikaela Peglow Pinz
LSLuiz F. Souza
Luiz F. Souza
NONatalia Oddone
Natalia Oddone
GFGerardo Ferrer-Sueta
Gerardo Ferrer-Sueta
MCMarcelo A. Comini
Marcelo A. Comini
FMFlavia Carla Meotti
Flavia Carla Meotti

1 March 2022 in International Journal for Innovation Education and Research
Verified
Journal Article
Open access
PDF file
PSPatricia Ferreira Schopf
Patricia Ferreira Schopf
MPMikaela Peglow Pinz
Mikaela Peglow Pinz
KMKetlyn Pereira da Motta
Ketlyn Pereira da Motta
VKVitor Pereira Klein
Vitor Pereira Klein
AMAlencar Machado
Alencar Machado
MSMichele Sagrillo
Michele Sagrillo
Alzheimer's disease is a worldwide health issue, and there are currently no treatments that can stop this disease. Oxidized graphene derivatives have gained prominence in use in biological systems due to their excellent physical-chemical characteristics, biocompatibility and ability to overcome the blood-brain barrier. Other substances highlighted are those of natural origin from the Amazon biome, such as tucuma, a fruit whose oil has been widely studied in therapeutic applications. Thus, the aim of this study was to investigate the action of graphene oxide, reduced graphene oxide and tucuma oil, isolated and combined, as an alternative for treatment of Alzheimer's disease through studies in silico, in vitro, in vivo and ex vivo. Computational simulation via docking was used to verify the affinity of the substances with the proteins β-amyloid and acetylcholinesterase, in which the reduced graphene oxide was the one that showed the most favorable interaction. The results of the ab initio simulation showed that the synergism between the nanostructures and the oil occurs through physical adsorption. The experimental results revealed that the substances and their combinations were nontoxic, both at the cellular and systemic level. In general, all treatments had positive results against induced memory deficit, but reduced graphene oxide was the most prominent, as it was able to protect against memory damage in all behavioral tests performed, with anticholinesterase activity and antioxidant effect. In conclusion, the reduced graphene oxide is, among the treatments studied, the one with great therapeutic potential to be investigated in the treatment of this disease.